logo-loader
AIM:HVO

hVIVO PLC

Receive alerts
Market:
AIM
Price
4.70 GBX
Day Change
-3.05%
Market Cap:
£32.37 m
52 weeks high
11.00
52 weeks low
4.31

In brief

hVIVO plc (Ticker: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.

The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.

With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.

  • Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.
  • Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.
  • Human Challenge Trials leverages hVIVO’s state-of-the-art quarantine facility in London – the largest of its kind worldwide – to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.
  • Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.

Snapshot

  • hVIVO appoints Caroline Shaw to board as Sullivan steps down
  • hVIVO a world leader in an expanding niche quietly making progress
  • Shore Capital upbeat hVIVO as record orderbook builds
  • hVIVO successfully completes pilot characterisation study for hMPV, prepares for challenge trials